AT-20494

N/A

Report date: 2022/04/02 11:35:21
NME

Base Information

Drug NameAT-20494
Drug Alias NameAT-20494
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMammalian target of Rapamycin (mTORC1) inhibitors
TargetsMammalian target of Rapamycin (mTORC1)
Therapy Area/IndicationsPolycystic Kidney, Autosomal Dominant
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAnakuria Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAnakuria Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsPolycystic Kidney, Autosomal Dominant
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A